arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Zoetis Inc.

ZTS
$71.68 ▼ -1.08 (-1.48%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
57 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
68
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

Zoetis Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $29.9B
Dividend Yield 0.74%
Revenue Growth 0.3%
Op. Margin
ROIC
FCF / Share $1.29
Trailing P/E 43.4x
Price / Book 9.4x
FCF Yield 1.8%
Debt / Equity 2.87
info Valuation on last close. End-of-day price, Sep 23, 2026.

57-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.47B
— +0.3%
Net Income Profit after all expenses
$691.00M
↓ -3.8%
FCF / Share Free cash flow per share
$1.29
↑ +86.9%
Long-Term Debt Long-term obligations
$9.05B
— 0.0%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
88
Returns
99
Financial Health
9
Cash Quality
58

Dividend History

Dividend / share · sourced from SEC filings
$2.03 Latest / share
+13.0% YoY
+20.3% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 57 quarters